Top Healthcare Technology Companies For 2015

Zynga Inc (NASDAQ:ZNGA) ain’t playing games today. The Multimedia & Graphics Software company is up on humongous volume. More than 75 million shares traded (as we type) thanks to an upgrade from UBS. Normally, ZNGA trades 23.97 million shares a day.

Analyst, Eric J. Sheridan upped the stock to a “Buy” from a “Neutral” rating with a flashy new price-target of $6 – 32.45% upside to target as of this keystroke.

Zynga Inc. develops, markets, and operates online social games as live services on the Internet, social networking sites, and mobile platforms. The company provides its games under the FarmVille, CityVille, FarmVille 2, ChefVille, CastleVille, Zynga Poker, Words With Friends, Scramble With Friends, Draw Something, Bubble Safari, Mafia Wars, Ayakashi, Horn, and Respawnables.

Top Healthcare Technology Companies For 2015: Masco Corporation (MAS)

Masco Corporation engages in the manufacture, distribution, and installation of home improvement and building products primarily in North America and Europe. The company operates through five segments: Cabinets and Related Products, Plumbing Products, Installation and Other Services, Decorative Architectural Products, and Other Specialty Products. The Cabinets and Related Products segment manufactures and sells stock and semi-custom assembled, and ready-to-assemble cabinetry for kitchen, bath, storage, home office, and home entertainment applications, as well as kitchen countertops, and integrated bathroom vanity and countertop solutions. The Plumbing Products segment offers single-handle and double-handle faucets, showerheads, handheld showers, valves, and toilets; tub and shower systems, bath and shower enclosure units, shower trays, and laundry tubs, as well as spas; and brass and copper plumbing system components, and other plumbing specialties. The Installation and Ot her Services segment sells installed building products, such as gutters, after-paint products, fireplaces, and garage doors, as well as insulation and insulation accessories, and roofing and other products. The Decorative Architectural Products segment produces architectural coatings, including paints, primers, specialty paint products, stains, and waterproofing products; and cabinet, door, window, and other hardware products. The Other Specialty Products segment manufactures and sells vinyl, fiberglass, and aluminum windows and patio doors; and manual and electric staple gun tackers, staples, and other fastening tools. The company offers its products to the home improvement and new home construction markets through mass merchandisers, hardware stores, home centers, homebuilders, distributors, and other outlets for consumers and contractors, as well as directly to the consumers. Masco Corporation was founded in 1929 and is headquartered in Taylor, Michigan.

Advisors’ Opinion:

  • [By Ben Eisen]

    Shares of Masco Corp. (MAS)  sank 7.4% after the home-improvement products maker reported its first-quarter earnings.

  • [By Sue Chang , Saumya Vaishampayan]

    Masco Corp. (MAS) shares slid 4.4%. The stock’s rating was lowered to underweight from hold at KeyCorp, according to Analyst Ratings Network.

Top Healthcare Technology Companies For 2015: DTE Energy Company(DTE)

DTE Energy Company, together with its subsidiaries, operates as an electric and natural gas utility company in Michigan. It also involves in non-utility operations. The company?s Energy Utility segment engages in the generation, purchase, distribution, and sale of electricity in southeastern Michigan. It generates electricity from various fuels, including coal, as well as from nuclear and hydro facilitates. As of December 31, 2010, this segment owned and operated approximately 674 distribution substations and approximately 412,100 line transformers; and supplied electricity to 2.1 million residential, commercial, and industrial customers in southeastern Michigan. The company?s Gas Utility segment engages in the purchase, storage, transmission, distribution, and sale of natural gas in Michigan. As of December 31, 2010, this segment?s distribution system included approximately 19,000 miles of distribution mains, 1,036,000 service lines, and 1,319,000 active meters. It also o wned approximately 2,000 miles of transmission lines that deliver natural gas; and supplied natural gas to approximately 1.2 million residential, commercial, and industrial customers throughout Michigan, as well as to approximately 17,000 customers in Adrian, Michigan. The company?s non-utility operations include natural gas pipelines and storage; unconventional gas exploration, development, and production; power and industrial projects, and coal transportation and marketing; and energy marketing and trading operations. Its customers include electric utilities, merchant power producers, integrated steel mills, and industrial companies. DTE Energy Company was founded in 1995 and is based in Detroit, Michigan.

Advisors’ Opinion:

  • [By Richard Stavros]

    Michigan-based ITC Holdings Corp (NYSE: ITC) is the largest electric transmission company in the US. The company is in charge of the electric transmission system formerly owned by DTE Energy Holding Co (NYSE: DTE) and CMS Energy Corp (NYSE: CMS).

  • [By Marie Mawad]

    European telecommunications companies are disposing of peripheral assets as they increase investments in high-speed mobile networks in their largest markets and cut debt. Last week, Deutsche Telekom AG (DTE) agreed to sell a 70 percent stake in its Scout24 Holding digital-classifieds business.

  • [By John Udovich]

    Small cap Plug Power Inc was formed in 1997 as a joint venture between Michigan utility owner DTE Energy Co (NYSE: DTE) and Mechanical Technology Inc (OTCMKTS: MKTY) to develop fuel-cell systems to power homes and small businesses. Plug Power Inc says it has revolutionized the material handling industry with cost-effective power solutions that increase productivity, lower operating costs and reduce carbon footprints as it manufactures a full suite of products designed to fit seamlessly into the existing battery compartment of all major OEM material handling equipment. In addition, the company says its GenDrive fuel cell is a superior alternative to lead-acid batteries for electric lift trucks in the $20 billion global material handling market.

  • [By John Udovich]

    Meanwhile, Plug Power Inc was formed in 1997 as a joint venture of Michigan utility owner DTE Energy Co (NYSE: DTE) and Mechanical Technology Inc (OTCMKTS: MKTY) to develop fuel-cell systems to power homes and small businesses. Plug Power Inc says it has revolutionized the material handling industry with cost-effective power solutions that increase productivity, lower operating costs and reduce carbon footprints as it manufactures a full suite of products designed to fit seamlessly into the existing battery compartment of all major OEM material handling equipment. The company also says that its GenDrive fuel cell is a superior alternative to lead-acid batteries for electric lift trucks in the $20 billion global material handling market.

Top Healthcare Technology Companies For 2015: ImmunoGen Inc.(IMGN)

ImmunoGen, Inc. engages in the research and development of targeted therapeutics for the treatment of cancer using cancer biology, monoclonal antibodies, and highly potent cell-killing agents. The company develops its products using its Targeted Antibody Payload (TAP) technology. Its product candidates include Trastuzumab emtansine (T-DM1), a Phase III clinical trial product for HER2+ breast cancer; lorvotuzumab mertansine (IMGN901), a Phase I clinical trial product, which targets CD56 found on small-cell lung cancer, Merkel cell carcinoma, multiple myeloma, ovarian cancers, carcinoid tumors, and other cancers of neuroendocrine origin; IMGN529, a pre-investigational new drug stage drug for CD37+ B-cell malignancies, such as non-Hodgkin’s lymphoma; and IMGN853, a preclinical stage product for cancers that overexpress folate receptor 1, including ovarian cancer. The company?s earlier-stage compounds in development stage comprise SAR3419, a Phase I clinical trial product for CD19+ B-cell malignancies, including non-Hodgkin’s lymphoma; SAR650984, a Phase I clinical trial product for CD38+ hematological malignancies; SAR566658, a phase one clinical trial product for DS6+ solid tumors; and BT-062, a Phase I product for multiple myeloma. It has collaboration agreements with Amgen, Inc.; Bayer Schering Pharma AG; Biogen Idec MA Inc.; Biotest AG; Genentech, Inc.; Novartis Institutes for BioMedical Research, Inc.; and sanofi-aventis U.S. LLC. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Advisors’ Opinion:

  • [By Bryan Murphy]

    It may not have blazed a trail into the young, immunology segment of the biotech industry the way Dendreon Corporation (NASDAQ:DNDN) did back in 2010 with the debut of Provenge. It may not have the same immunology pipeline (and company size) that ImmunoGen, Inc. (NASDAQ:IMGN) boasts. One thing is pretty certain about cancer-immunotherapy developer CEL-SCI Corporation (NYSEMKT:CVM) right now, however – its stock may be poised to dole out a much bigger foreseeable-future reward than DNDN or IMGN are.

  • [By Sean Williams]

    A moat of competition, but plenty of upside
    However, investors would probably be wise not to get too carried away with yesterday’s news given that another therapy — which I would certainly call revolutionary — known as Kadcyla for HER2-positive breast cancer was just approved in February. Kadcyla, developed by Roche and ImmunoGen (NASDAQ: IMGN  ) piggybacks a toxin on an antibody and, using ImmunoGen’s proprietary targeted antibody payload technology, delivers a higher dose of toxin directly to the targeted cancer, which has a signature protein that causes the release of the toxin from the antibody. In late-stage trials, Kadcyla improved PFS by 50% over the placebo to 9.6 months.

  • [By Sean Williams]

    A new type of treatment that involves utilizing antibodies to carry toxins also shows plenty of promise. These antibodies work by releasing a toxin once they come into contact with very specific protein signatures released by the targeted cancer cells, and could be the key to targeted cancer treatments. One example is Roche and ImmunoGen’s (NASDAQ: IMGN  ) Kadcyla, which was approved by the FDA in February as a second-line treatment for HER2-positive breast cancer. The drug combines the HER2 protein-blocking power of Herceptin and uses ImmunoGen’s targeted antibody payload technology to deliver the chemotherapy agent directly to the cancer cells. With minimal healthy tissue death, Kadcyla improved progression-free survival and median overall survival by 3.2 months and 5.8 months, respectively, as compared to another current standard of treatment, which is GlaxoSmithKline’s and Roche’s Xeloda.

  • [By Sean Williams]

    Now what: We’re still in the top of the second inning of a nine-inning game here, but ADCs certainly appear to be the future of cancer therapy — at least one path to treating it. Immunomedics still has a long road to climb as its two ADC peers are much further along in their development process. ImmunoGen (NASDAQ: IMGN  ) , for instance, already has an FDA-approved drug for late-stage HER2-positive breast cancer known as Kadcyla that utilizes the company’s proprietary targeted-antibody payload technology (the same concept as ADCs with a different name) in combination with Roche’s Herceptin. In trials, this combo extended median overall survival by 5.8 months over the placebo to 30.9 months. Something similar can be said for Seattle Genetics and its ADC pipeline.

Top Healthcare Technology Companies For 2015: Intellipharmaceutics International Inc.(IPCI)

Intellipharmaceutics International Inc. engages in the research, development, and manufacture of novel or generic controlled and targeted release oral solid dosage drugs. The company?s patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of various existing and new pharmaceuticals. It has a pipeline of products in various stages of development in therapeutic areas, including neurology, cardiovascular, and gastrointestinal tract, pain, and infection. The company?s lead generic product under development includes generic Focalin XR (dexmethylphenidate hydrochloride), an extended-release capsule for the treatment of attention deficit hyperactivity disorder. Intellipharmaceutics has a license and commercialization agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic Focalin XR. The company also has five generic products filed with the FDA, including a gene r ic of Effexor XR (venlafaxine hydrochloride), an extended-release capsule for depression; Protonix (pantoprazole sodium), a delayed-release tablet for conditions associated with gastroesophageal disease; Glucophage XR (metformin hydrochloride), an extended-release tablet for managing type 2 diabetes; Seroquel XR (quetiapine fumarate), an extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; and Lamictal XR (lamotrigine), an extended-release tablet for the treatment of anti-convulsant for epilepsy. Its lead non-generic product under development is Rexista (oxycodone), an abuse- and alcohol-deterrent controlled-release oral oxycodone hydrochloride formulation for the relief of pain. The company also has a under late stage development product, such as Coreg CR (carvedilol phosphate), an extended-release capsule for hypertension and heart conditions. IntelliPharmaCeutics International Inc. was founded in 1998 and is based i n Toronto, Canada.

Advisors’ Opinion:

  • [By Roberto Pedone]

    A pharmaceutical player that’s starting to trend within range of triggering a big breakout trade is IntelliPharmaCeutics (IPCI), which specializing in the research, development and manufacture of generic controlled-release and targeted-release oral solid dosage drugs. This stock has been on fire over the last three months, with shares up a whopping 99%.

    If you take a look at the chart for IntelliPharmaCeutics, you’ll notice that this stock has been uptrending a bit over the last few weeks, with shares moving higher from its low f $3.12 to its recent high of $4.37 a share. During that uptrend, shares of IPCI have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of IPCI within range of triggering a big breakout trade above some key overhead resistance levels.

    Traders should now look for long-biased trades in IPCI if it manages to break out some near-term overhead resistance levels at $4.37 to $4.62 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.31 million shares. If that breakout triggers soon, then IPCI will set up to re-test or possibly take out its 52-week high at $6.46 a share.

    Traders can look to buy IPCI off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.36 or at its 50-day moving average of $3.13 a share. One could also buy IPCI off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top Healthcare Technology Companies For 2015: Lexicon Pharmaceuticals Inc.(LXRX)

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of drug candidates for the treatment of various human diseases. The company utilizes gene knockout technologies and an integrated platform of medical technologies to systematically study the physiological and behavioral functions of approximately 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as drug targets. Its portfolio of orally-delivered small molecule compounds that have completed or are presently conducting phase 2 clinical trails includes LX4211 for the treatment of type 2 diabetes; LX1031 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX1032 for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of rheumatoid arthritis and other autoimmune diseases. The company also develops LX1033, an orally-delivered small molecule compound that is in phase 1 clinical trails for the treatment of irritable bowel syndrome and other gastrointestinal disorders. In addition, it develops three orally-delivered small molecule compounds in preclinical development stage that include LX7101 for treatment of glaucoma; LX5061 for the treatment of osteoporosis; and LX2311 for the treatment of autoimmune diseases. Further, the company has small molecule compounds from various additional drug discovery programs in various stages of preclinical research. It has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. The company also has a series of agreements with Symphony Icon, Inc. for the financing of clinical development programs; and an alliance with Nuevolution A/S to access Nuevolution?s Chemetics chemistry technology. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Advisors’ Opinion:

  • [By Lauren Pollock]

    Among the companies with shares expected to actively trade in Tuesday’s session are OncoMed Pharmaceuticals Inc.(OMED), Lexicon Pharmaceuticals Inc.(LXRX) and Krispy Kreme Doughnuts Inc.(KKD)

  • [By Brian Pacampara]

    Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, biotech company Lexicon Pharmaceuticals (NASDAQ: LXRX  ) has received a distressing two-star ranking.

  • [By Lauren Pollock]

    Lexicon Pharmaceuticals Inc.(LXRX) said a pilot study of a treatment for ulcerative colitis showed certain clinical benefits, but the results lacked other findings that would indicate a large enough impact to move ahead on developing the treatment for this particular use. Shares dropped.

  • [By Bryan Murphy]

    Over the past few weeks, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) and Decision Diagnostics Corp. (OTCBB:DECN) have dominated the diabetes diagnostics and diabetes treatment landscape. Shares of LXRX jumped 20% on Tuesday following news that one of the key drugs in its pipeline showed more than enough efficacy in its clinical trials. DECN shares are up more than 250% on the heels of an almost-assured victory in its patent lawsuit against industry giant Johnson & Johnson (NYSE:JNJ). Anyone looking for a new trade in the diabetes diagnostics space, however, may want to look past overbought Lexicon Pharmaceuticals and Decision Diagnostics at this point, and instead turn their attention to newly-budding Neurometrix Inc. (NASDAQ:NURO).

Top Healthcare Technology Companies For 2015: Rexnord Corp (RXN)

Rexnord Corporation (Rexnord), incorporated on July 13, 2006, is a multi-platform industrial company. The Company comprises of two platforms, Process & Motion Control and Water Management. Rexnord’s Process & Motion Control product portfolio includes gears, couplings, industrial bearings, aerospace bearings and seals, FlatTop chain, engineered chain and conveying equipment, and are marketed and sold globally under brands, including Rexnord, Rex, Falk and Link-Belt. Its Water Management platform operates in the commercial construction market for water management products and the municipal water and wastewater treatment markets. Its Water Management product portfolio includes drainage products, flush valves and faucet products, backflow prevention pressure release valves, PEX piping and engineered valves and gates for the water and wastewater treatment markets. These products are marketed and sold through brand names, including Zurn, Wilkins, VAG, GA, Rodney-Hunt and Fonta ine. In August 2013, Rexnord Corp announced that it has acquired the assets of Micro Precision Gear Technology Limited. In December 2013, Rexnord acquired Precision Gear Holdings, LLC (PGH). PGH has two operating subsidiaries, Merit Gear LLC and Precision Gear LLC.

Process & Motion Control

The Company’s Process & Motion Control platform designs, manufactures, markets and services mechanical components used within complex systems. The Company sells its Process & Motion Control products into a diverse group of end markets, including mining, general industrial applications, cement and aggregates, agriculture, forest and wood products, petrochemical, energy, food and beverage, aerospace and wind energy. The Company is a manufacturer of gear drives and gear sets for the heavy duty industrial market. Its gear drives, service and gear sets are used in a number of heavy duty industries. These primary industries include the natural resource extraction, s teel, pulp and paper, chemical, forest and wood industries. ! Rexnord manufactures a range of heavy duty, medium and light duty gear drives used for bulk material handling, mixing, pumping and general gearing applications. It also operates a gear service and repair business through its Product Service group (Prager and Renew). Its Couplings are primarily used in high-speed, high-torque applications and are the interface between two shafts that permit power to be transmitted from one shaft to the other. Rexnord’s couplings are sold to a range of end markets, including the petrochemical and refining, wood processing, chemical, power generation and natural resources industries. Couplings comprise of the grid, flexible disc, elastomeric and gear product lines and are sold under the Steelflex, Thomas, Omega, Rex, Viva, Wrapflex, Lifelign, True Torque, Addax and Autogard brand names.

The Company primarily produces mounted bearings, which are offered in a range of specialized housings to suit specific industrial applications. Its FlatTop chain provides a continuous conveying surface that is critical to high-speed operations, such as those used to transport cans and bottles in beverage-filling operations, and is primarily sold to the food and beverage, consumer products, warehousing and distribution, and parts processing industries. The Company supplies its aerospace bearings and seals to the commercial aircraft, military aircraft and regional jet end markets for use in door systems, engine accessories, engine controls, engine mounts, flight control systems, gearboxes, landing gear and rotor pitch controls. Rexnord’s aerospace bearings and seals products consist of rolling element airframe bearings sold under the Shafer brand name, slotted-entry and split-ball sliding bearings sold under the PSI brand name and aerospace seals that are sold under the Cartriseal brand name, which are primarily sold for use in both aerospace and industrial applications.

The Company’s special compone nts products consist of three primary product lines: electri! c motor b! rakes, miniature Process & Motion Control components and security devices for utility companies. These products are manufactured by its businesses, such as Stearns, W.M. Berg and Highfield. Stearns’ products are used in a range of applications, including steel mills, oil field equipment, pulp processing equipment, large textile machines, rubber mills, metal forming machinery and dock and pier handling equipment. W.M. Berg sells its products to a range of markets, including aerospace, semiconductor, medical equipment, robotics, instrumentation, office equipment and satellite communications. Highfield’s products are sold to a range of markets, including electric, gas, water, telecommunications, utilities and plumbing and heating.

The Company’s conveying equipment and industrial chain products are used in various applications in a number of industries, including food and food processing, beverage and container, mining, construction and agricultural equipment , hydrocarbon processing and cement and aggregates processing. Its primary products include conveying equipment, engineered steel chain, and roller chain. Its conveying equipment product group provides design, assembly, installation and after-the-sale services primarily to the mining, cement and aggregates industries. Its products include engineered elevators, conveyors and components for medium to heavy duty material handling applications. The Company’s engineered steel chain products are sold under the Link-Belt and Rexnord brand names. These products are used in a number of applications, including cement elevators, construction and mining equipment and conveyors, and they are supplied to the cement and aggregates, energy, food and beverage, and forest and wood products industries.

Water Management

The Company’s Water Management platform designs, procures, manufactures and markets products that provide and enhance water quality, safety, flow control and conservation. The Water Management product port! folio inc! ludes professional grade specification drainage products, flush valves and faucet products, engineered valves and gates for the water and wastewater treatment market and PEX piping and are marketed and sold through brand names, including Zurn, Wilkins, VAG, GA, Rodney Hunt and Fontaine. Rexnord’s Water Management platform has a network of approximately 1,100 independent sales representatives across approximately 210 sales agencies in North America, who work with local engineers, contractors, builders and architects to specify its products for use in construction projects. Its water control and safety products are sold under the Wilkins brand name and encompass a variety of valves, including backflow preventers, fire system valves, pressure reducing valves and thermostatic mixing valves. These products are sold into the commercial and industrial construction applications, as well as the fire protection, waterworks and irrigation end markets.

Zurn’s commercia l brass products include manual and sensor operated flush valves marketed under the Aquaflush, AquaSense, AquaVantage and HydroVantage brand names and heavy duty commercial faucets marketed under the AquaSpec brand name. Water conserving fixtures are marketed under the EcoVantage and Zurn One brand names. These products are used in office buildings, schools, hospitals, airports, sports facilities, convention centers, shopping malls, restaurants and industrial production buildings. The Zurn One Systems integrate commercial brass and fixtures into plumbing systems. PEX is its product line manufactured out of cross-linked polyethylene into tubing and is suited for high temperature and pressure fluid distribution piping. Its PEX products include lines of pipe, fittings, valves and installation tools for both potable water and radiant heating systems. Its water and wastewater products are sold under the VAG, GA, Rodney Hunt and Fontaine brand names and are used to control the flo w of water and wastewater throughout the water cycle from ra! w water t! hrough collection, distribution and wastewater treatment. Products include automatic control valves, check valves, air valves, butterfly valves, water control gates, hydrants, actuation systems, and other specialized products for municipal, industrial, and hydropower applications. Its product lines are primarily sold into the water supply and treatment markets worldwide.

Advisors’ Opinion:

  • [By Ben Levisohn]

    Each month, Credit Suisse’s small-cap strategists ask the firm’s analyst to name their favorite small- and mid-cap stocks. This month, six new stocks made the list: RPM International (RPM), SunCoke Energy (SXC), Zions Bancorp (ZION), Signature Bank (SBNY), Edwards Lifesciences (EW) and Rexnord (RXN).

  • [By Seth Jayson]

    Rexnord (NYSE: RXN  ) reported earnings on May 21. Here are the numbers you need to know.

    The 10-second takeaway
    For the quarter ended March 31 (Q4), Rexnord met expectations on revenues and beat expectations on earnings per share.

  • [By Eric Volkman]

    A sizable bloc of Rexnord (NYSE: RXN  ) will soon be in different hands if a secondary offering goes as planned. The company announced that “certain funds affiliated with” Apollo Global Management (NYSE: APO  ) are floating a 6.5 million-share stake in an underwritten public offering. The price is $16 per share. Additionally, the company’s underwriters have been granted a purchase option for up to an additional 975,000 shares.

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Rexnord (NYSE: RXN  ) , whose recent revenue and earnings are plotted below.